Cytokinetics Announces Opening of Second Cohort in Phase IIb Clinical Trial of ... MarketWatch (press release) The primary objective of this trial is to evaluate the effect of 48 hours of intravenous omecamtiv mecarbil compared to placebo on dyspnea (shortness of breath) in patients with left ventricular systolic dysfunction hospitalized for acute heart failure ... |
